MDS 2023 | Validation of non-invasive AI diagnostic tool for MDS
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, describes the features of a novel web-based tool using artificial intelligence (AI) to assist in the diagnosis or exclusion of myelodysplastic syndromes (MDS). Prof. Mittelman explains that this model, which has recently been validated in a new cohort of patients with MDS, can help avoid bone marrow examination, which is associated with significant drawbacks. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Research Funding; Takeda: Honoraria, Research Funding; Janssen: Research Funding; Roche: Research Funding; BMS: Research Funding; Celgene: Research Funding; Medison: Research Funding; Gilead: Research Funding.
